The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible.
 
Petros Grivas
Consulting or Advisory Role - 4D Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Dyania Health; EMD Serono; Exelixis; Genentech; GlaxoSmithKline; Guardant Health; Immunomedics; Infinity Pharmaceuticals; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Regeneron; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); EMD Serono (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Michiel Simon Van Der Heijden
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - 4SC (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Ipsen; Merck Sharp & Dohme (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche
Other Relationship - Bayer (I)
 
Arlene O. Siefker-Radtke
Consulting or Advisory Role - AstraZeneca; Basilea; Bavarian Nordic; Bristol-Myers Squibb; EMD Serono; Genentech; Janssen; Merck; Mirati Therapeutics; NCCN; Nektar; Seagen
Research Funding - Basilea; BioClin Therapeutics; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme; Michael and Sherry Sutton Fund for Urothelial Cancer; Nektar; NIH; Takeda
Patents, Royalties, Other Intellectual Property - Methods of characterizing and treating molecular subsets of muscle-invasive bladder cancer.
 
Hernan Cutuli
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Merck Sharp & Dohme Oncology
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Merck Sharp & Dohme Oncology; Pfizer
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Merck Sharp & Dohme Oncology; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen; Merck Sharp & Dohme Oncology
 
Anila H. Qureshi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Stephanie Kreiser
Employment - Bristol-Myers Squibb; Bristol-Myers Squibb (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb; Bristol-Myers Squibb (I); Pfizer; Pfizer (I)
Other Relationship - Bristol-Myers Squibb; Bristol-Myers Squibb (I)
 
Moana Hodari
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Shruthi Ravimohan
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Bayer; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; EMD Serono; Exelixis; Janssen; Novartis; Pfizer; Roche/Genentech; Seagen; TTC Oncology
Research Funding - Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Newlink Genetics